Based on previous studies that showed equal distribution of 177Lu- and 161/152Tb-labeled tumor targeting agents (including DOTA-folate14, DOTANOC19 and PSMA-61716), it was assumed that 149Tb-PSMA-617 and 177Lu-PSMA-617 would distribute equally in the body. Here, FOLH1 is linked to neoplasm.